systemic%20lupus%20erythematosus%20(pediatric)
SYSTEMIC LUPUS ERYTHEMATOSUS (PEDIATRIC)
Systemic lupus erythematosus is a chronic, multisystem, inflammatory, autoimmune disorder characterized by formation of autoantibodies directed against self-antigens and immune-complex formation.
It can be suspected when ≥2 organ systems are involved.
It is predominantly diagnosed in females of childbearing age, rarely diagnosed before 8 years old.
Clinical presentation varies in different patients and the disease activity varies over time in a single patient. Majority of patients have arthralgia of the hand.

Principles of Therapy

Patients require individualized therapy depending on disease manifestations, activity & severity

Goals of therapy

  • Control disease manifestations
  • Allow the child to have a good quality of life w/o major exacerbations
  • Prevent serious organ damage that adversely affects function or life span
  • Prevent adverse effects of the drugs used

Pharmacotherapy

Corticosteroids

Oral Corticosteroids

  • Patients w/ mild SLE do not normally require use of systemic corticosteroids but there are patients who has low quality of life if not given low-dose corticosteroids
  • Lowest possible dose should be used for maintenance therapy
  • Used as initial therapy for severe discoid lupus erythematosus or lupus vasculitis
  • Low-dose corticosteroids may be added to Hydroxychloroquine for fatigue & fever
  • High-dose corticosteroids are necessary for refractory manifestations of SLE & for severe organ systems’ manifestations esp CNS, renal & hematologic manifestations
    • Patients w/ milder forms of renal manifestations (eg mesangial glomerulonephritis & focal proliferative glomerulonephritis) may respond to corticosteroids
    • Show improved survival in patients w/ severe forms of SLE nephritis
    • May also be useful in severe, life-threatening thrombocytopenia & hemolytic anemia
    • May also be useful in pleuritis or pericarditis
  • Decreases inflammation by suppression of the immune system
    • Decreases lymphocyte volume & activity, PMN migration, capillary permeability
    • High doses over periods >2-3 wk, suppress adrenal function
  • Corticosteroid use should be tapered, & if possible withdrawn, as soon as desired response is observed (control of inflammatory manifestations) to avoid toxicity
Topical Corticosteroids
  • Helpful for discoid lesions esp on the scalp
  • Use a less potent steroid on the face because it is more prone to atrophy
Parenteral Corticosteroids
  • Pulse therapy w/ IV corticosteroids in combination w/ immunosuppressive therapy is recommended for ClassIII/IV SLE patients w/ confirmed glomerulonephritis
Hydroxychloroquine
  • Used for skin & joint manifestations
    • Useful for patients w/ skin disease that are unresponsive to topical corticosteroids & in patients w/ arthritis that does not respond to NSAID
  • Also used for preventing flares & other constitutional symptoms
  • Inhibits chemotaxis of eosinophils & locomotion of neutrophils & impairs complement-dependent antigen-antibody reactions
  • Recommended as background treatment for Class III/IV SLE patients w/ nephritis
    • Patients w/ continuing treatment w/ Hydroxychloroquine showed less renal damage as compared to those on placebo

Immunosuppressants

Choice of immunosuppressant will depend on nature & severity of disease manifestation

  • These agents act as immunosuppressive, cytotoxic & anti-inflammatory agents
    • In the treatment of severe CNS & severe glomerulonephritis, thrombocytopenia & hemolytic anemia, high dose glucocorticoids & immunosuppressants are used
    • Concomitant use w/ corticosteroids allows lower doses of immunosuppressants
Azathioprine
  • May be used as the initial immunosuppressant for SLE nephritis
  • Antagonizes purine metabolism & inhibits synthesis of DNA, RNA & proteins
  • An alternative to Cyclophosphamide & a steroid-sparing agent in nonrenal disease
  • May decrease proliferation of immune cells, resulting in lower autoimmune activity
Belimumab
  • The first US FDA-approved biologic therapy for the treatment of SLE
  • A human monoclonal antibody that binds to soluble B-lymphocyte stimulator (BLyS/BAFF) to reduce disease activity
  •  Used for active, autoantibody-positive SLE patients currently on standard therapy
  • Not recommended for patients w/ severe active lupus nephritis or severe active CNS disease
  • Studies have shown that patients on Belimumab therapy experienced reduced risk of severe flares, improved health-related quality of life & reduced steroid use as compared to those on placebo
Cyclophosphamide
  • Used as the initial immunosuppressant for SLE nephritis
    • Concomitant use w/ Prednisone is the standard treatment for lupus nephritis as it helps preserve renal function
  • Useful for severe SLE w/ involvement of different organ systems (eg severe CNS involvement, vasculitis or lupus nephritis)
  • As an alkylating agent, may involve cross-linking of DNA, which may interfere w/ growth of normal & neoplastic cells
Intravenous immune globulin (IVIg)
  • Used as immunosuppression in serious SLE flares
  • Neutralizes circulating myelin antibodies through anti-idiotypic antibodies
    • Down-regulates proinflammatory cytokines, including interferon-gamma
    • Blocks receptors on macrophages, suppresses inducer T & B cells & augments suppressor T cells
    • Blocks complement cascade, promotes remyelination & may increase colony stimulating factor Immunoglobulin G
Methotrexate
  • May be used as the initial immunosuppressant for severe arthritis
  • Blocks purine synthesis, increases anti-inflammatory adenosine concentration at sites of inflammation
Nonsteroidal anti-inflammatory drugs (NSAIDs)
  • These drugs provide symptomatic relief of fever, arthritis & mild serositis
  • Inhibit inflammatory reactions & pain by decreasing prostaglandin synthesis
  • SLE patients have a high incidence of NSAID-induced hepatotoxicity
Sunscreen
  • Patients w/ SLE should apply sunscreen w/ at least an SPF of 15 to prevent dermal or systemic disease flares upon exposure to ultraviolet light



Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
17 Apr 2019
A family history of testicular cancer (TC), carcinoma, mesothelioma, sarcoma, malignant melanoma and malignant neuroepithelial tumours appears to increase the risk of paediatric and young adults’ TC, suggests a recent study.
19 Jul 2016
Acute gastroenteritis (AGE) remains a significant contributor to paediatric disease burden across the world in the 21st century. Rehydration remains the mainstay of therapy, while pharmacotherapy may have adjunctive benefits. We seek to review the evolution in management strategies of paediatric AGE, in particular the child with viral AGE.
Joyce Lam Ching Mei, 28 Mar 2019
April 17 marks World Haemophilia Day, and this year’s theme is  “Reaching Out – The First Step to Care”. Adjunct Assoc Prof Joyce Lam Ching Mei, head of the Haematology Laboratory and Blood Bank and senior consultant from the Paediatric Haematology/Oncology Service at KK Women’s and Children’s Hospital, Singapore, speaks to Elaine Soliven on the importance of recognizing and managing bleeding disorders in primary care.
Stephen Padilla, 28 Feb 2018
The 2-year preventive oral health programme in Singapore has succeeded in lowering the presence of severe early childhood caries (SECC) among infants and toddlers, driven primarily by the implementation of targeted behaviour modifications, such as reducing the consumption of sweetened milk and increased use of fluoridated toothpaste, reports a study.